Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 2/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.41 |
| ▸ | RAF1 | P04049 | 2/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.40 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL876289 | 0.92 | CHEK2 (0.47) | CHEK2ARKDRPPARGPPARA | |
| SCHEMBL15096322 | 0.88 | MEN1 (0.40) | CHEK2ARKDRSCN9ABRAF | |
| SCHEMBL15823461 | 0.88 | AR (0.56) | CHEK2ARKDR | |
| SCHEMBL364785 | 0.86 | ALDH1A1 (0.55) | CHEK2ARSCN9ARAF1BRAF | |
| SCHEMBL16199415 | 0.86 | CHEK2 (0.41) | CHEK2ARKDRPPARGPPARA | |
| SCHEMBL875970 | 0.85 | AR (0.54) | ARKDR | |
| SCHEMBL29985730 | 0.84 | AR (0.46) | CHEK2ARKDRPPARGPPARA | |
| SCHEMBL875004 | 0.84 | AR (0.46) | CHEK2ARKDRPPARGPPARA | |
| SCHEMBL8550194 | 0.84 | AR (0.44) | ARSCN9A | |
| SCHEMBL16362941 | 0.83 | AR (0.41) | CHEK2ARKDRPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2731935-B1 | FUNGICIDAL SUBSTITUTED 2-[2-HALOGENALKYL-4-(PHENOXY)-PHENYL]-1-[1,2,4]TRIAZOL-1-YL-ETHANOL COMPOUNDS | BASF AGRO BV (NL) | 2016-03-09 | — | — | EP | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LTD (GB) | 2014-12-25 | — | — | US | disclosed |
| US-8871928-B2 | Tricyclic compounds, preparation methods, and their uses | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| WO-2012037782-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | GLAXO GROUP LIMITED (GB) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378487-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CHEK2 3892/4885AR 3517/4885KDR 1285/4885 |
| US-20130178488-A1 | TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES | LIPG, PCSK9, ENPP2 | CHEK2 3892/4885AR 3517/4885KDR 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.